Targeting protein-protein interaction interfaces in COVID-19 drug discovery.
Comput Struct Biotechnol J
; 19: 2246-2255, 2021.
Article
in English
| MEDLINE | ID: covidwho-1184914
ABSTRACT
To date, the COVID-19 pandemic has claimed over 1 million human lives, infected another 50 million individuals and wreaked havoc on the global economy. The crisis has spurred the ongoing development of drugs targeting its etiological agent, the SARS-CoV-2. Targeting relevant protein-protein interaction interfaces (PPIIs) is a viable paradigm for the design of antiviral drugs and enriches the targetable chemical space by providing alternative targets for drug discovery. In this review, we will provide a comprehensive overview of the theory, methods and applications of PPII-targeted drug development towards COVID-19 based on recent literature. We will also highlight novel developments, such as the successful use of non-native protein-protein interactions as targets for antiviral drug screening. We hope that this review may serve as an entry point for those interested in applying PPIIs towards COVID-19 drug discovery and speed up drug development against the pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Etiology study
Language:
English
Journal:
Comput Struct Biotechnol J
Year:
2021
Document Type:
Article
Affiliation country:
J.csbj.2021.04.003
Similar
MEDLINE
...
LILACS
LIS